Oncodesign Société Anonyme

ENXTPA:ALONC Stock Report

Market Cap: €99.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Oncodesign Société Anonyme Balance Sheet Health

Financial Health criteria checks 3/6

Key information

232.0%

Debt to equity ratio

€26.25m

Debt

Interest coverage ration/a
Cash€25.45m
Equity€11.31m
Total liabilities€47.75m
Total assets€59.06m

Recent financial health updates

Recent updates

Need To Know: The Consensus Just Cut Its Oncodesign Société Anonyme (EPA:ALONC) Estimates For 2022

Apr 16
Need To Know: The Consensus Just Cut Its Oncodesign Société Anonyme (EPA:ALONC) Estimates For 2022

Calculating The Intrinsic Value Of Oncodesign Société Anonyme (EPA:ALONC)

Jun 08
Calculating The Intrinsic Value Of Oncodesign Société Anonyme (EPA:ALONC)

Are Oncodesign Société Anonyme (EPA:ALONC) Investors Paying Above The Intrinsic Value?

Feb 22
Are Oncodesign Société Anonyme (EPA:ALONC) Investors Paying Above The Intrinsic Value?

Financial Position Analysis

Short Term Liabilities: ALONC's short term assets (€42.3M) exceed its short term liabilities (€26.5M).

Long Term Liabilities: ALONC's short term assets (€42.3M) exceed its long term liabilities (€21.3M).


Debt to Equity History and Analysis

Debt Level: ALONC's net debt to equity ratio (7.1%) is considered satisfactory.

Reducing Debt: ALONC's debt to equity ratio has increased from 5.5% to 232% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ALONC has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALONC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/23 12:28
End of Day Share Price 2022/12/08 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncodesign Société Anonyme is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary WaandersBryan Garnier & Co
Victor FlochBryan Garnier & Co
Fanny MeindreCIC Market Solutions (ESN)